Prosecution Insights
Last updated: April 19, 2026
Application No. 16/556,765

COMPOSITION, DICHROIC SUBSTANCE, LIGHT ABSORPTION ANISOTROPIC FILM, LAMINATE, AND IMAGE DISPLAY DEVICE

Non-Final OA §102
Filed
Aug 30, 2019
Examiner
CHICKS, ASHLI ARIANA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujifilm Corporation
OA Round
7 (Non-Final)
65%
Grant Probability
Favorable
7-8
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allow Rate
49 granted / 75 resolved
+5.3% vs TC avg
Strong +44% interview lift
Without
With
+43.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
37 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
29.9%
-10.1% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 75 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1, 5-11, and 21-26 are pending. Claims 6–10 and 21-24 are withdrawn. Claims 1, 5, 11 and 25-26 are rejected. Response to Amendment/Arguments Applicant’s amendments and the translation of the foreign priority document have overcome the previously presented rejections. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 5 and 11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 4007-22-1, entered on November 16th, 1984. CAS Registry No. 4007-22-1 reads on claims 1, 5, and 11 where R21 is a halogen electron withdrawing group, m21 is 1, R22 is alkoxy, m22 is 2, one R23 is an alkoxycarbonyl electron withdrawing group and the other is hydroxy, and m23 is 0: PNG media_image1.png 200 400 media_image1.png Greyscale . The compound above has a CLogP of 10.448 calculated in ChemDraw (see OA appendix). Regarding the maximum wavelength limitations, the compound inherently possess this characteristic as it meets the limitations of the present claims. Claims 1, 5, 11 and 25-26 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 97987-21-8, entered on September 16th, 1985, cited in the OA filed 02/01/2024. CAS Registry No. 97987-21-8 is depicted below and reads on claims 1, 5, 11 and 25-26 where R21 and R23 are substituents where two of each are a halogen electron withdrawing group and one is an alkoxy group substituted by aralkyl (methoxy substituted by benzyl), m21 and m23 are 3, and m22 is 0: PNG media_image2.png 200 400 media_image2.png Greyscale . The compound above has a CLogP of 14.954 calculated in ChemDraw (see OA appendix). Regarding the maximum wavelength limitations, the compound inherently possess this characteristic as it meets the limitations of the present claims and is of similar structure to the compounds present in Examples I-1 to I-19, particularly I-1. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ASHLI A CHICKS whose telephone number is (571)270-0582. The examiner can normally be reached M-Th 7 a.m.- 5 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph K McKane can be reached at 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A.C./Examiner, Art Unit 1626 /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 30, 2019
Application Filed
Aug 30, 2019
Response after Non-Final Action
Sep 29, 2022
Response Filed
Dec 21, 2022
Non-Final Rejection — §102
Apr 03, 2023
Interview Requested
Apr 12, 2023
Applicant Interview (Telephonic)
Apr 12, 2023
Examiner Interview Summary
Apr 20, 2023
Response Filed
Jul 21, 2023
Final Rejection — §102
Jul 28, 2023
Applicant Interview (Telephonic)
Jul 28, 2023
Examiner Interview Summary
Oct 12, 2023
Response after Non-Final Action
Nov 21, 2023
Response after Non-Final Action
Nov 21, 2023
Request for Continued Examination
Nov 26, 2023
Response after Non-Final Action
Jan 26, 2024
Non-Final Rejection — §102
Apr 11, 2024
Response Filed
Jul 24, 2024
Final Rejection — §102
Oct 16, 2024
Response after Non-Final Action
Oct 23, 2024
Response after Non-Final Action
Oct 30, 2024
Request for Continued Examination
Nov 04, 2024
Response after Non-Final Action
Feb 06, 2025
Non-Final Rejection — §102
Apr 17, 2025
Applicant Interview (Telephonic)
Apr 17, 2025
Examiner Interview Summary
May 06, 2025
Response Filed
Aug 07, 2025
Final Rejection — §102
Oct 21, 2025
Response after Non-Final Action
Dec 03, 2025
Request for Continued Examination
Dec 08, 2025
Response after Non-Final Action
Dec 17, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589107
COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE AND MOGROSIDE, AND APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12590088
JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12564552
ORAL PRODUCT WITH A BASIC AMINE AND AN ION PAIRING AGENT
2y 5m to grant Granted Mar 03, 2026
Patent 12552801
NEW INDAZOLE DERIVATIVES
2y 5m to grant Granted Feb 17, 2026
Patent 12540130
SUBSTITUTED PYRROLIDINE AMIDES IV
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+43.9%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 75 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month